Month: October 2026

MIAMI, Oct. 29, 2026 (GLOBE NEWSWIRE) — SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced that its third quarter 2026 financial results will be issued on the morning of Thursday, November 5, 2026. Management will host a conference call and webcast at 08:30 AM ET to discuss the results and provide business updates.

To access the live conference call, participants may register here.

Conference Details:

Conference Date: Thursday, November 5, 2026
Conference Time: 08:30 AM ET
U.S. Dial-in: 1-877-704-4453
International Dial-in: 1-201-389-0920
Conference ID: 13762793
Conference Call Name: SAB BIO Q3 2026 Earnings Call

Following the conference call, a replay of the audio webcast will be available under the Investors & Media section of the Company’s website at www.sab.bio.

About SAB BIO
SAB BIO is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. Using advanced genetic engineering and antibody science, SAB BIO developed a proprietary technology which holds the potential to generate additional novel therapeutic candidates utilizing the human immune response, without the need for human donors or convalescent plasma. SAB BIO has optimized genetic engineering in the development of transchromosomic cattle, or Tc-Bovine, to produce hIgG. SAB BIO’s drug development production system is able to generate a diverse repertoire of specifically targeted, high-potency, hIgGs that can address a wide range of serious unmet needs in human diseases. The Company’s lead candidate, SAB-142, targets autoimmune T1D with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. SAB-142 is being evaluated in two clinical trials: the registrational Phase 2b SAFEGUARD study for those newly diagnosed with Stage 3 T1D and the investigator-led Phase 3 PRISE-hATG study for people up to two years following a Stage 3 T1D diagnosis. For more information, visit www.sab.bio.

CONTACTS
Investor Relations:
Christine Ryan
ir@sab.bio

Media:
Sheila Carlson
media@sab.bio

TOKYO, Japan, Oct. 29, 2026 (GLOBE NEWSWIRE) — CTW (Nasdaq: CTW) (“CTW” or “the Company”), a leading game platform company providing global access to web-based games through its flagship platform, G123.jp, today announced that its leadership will participate in the BMO Capital Markets Technology and Innovation Leaders Conference on November 12, 2026.

BMO Capital Markets Technology and Innovation Leaders Conference

Date: November 12, 2026
Location: InterContinental New York Barclay – 111 East 48^th Street, New York, NY

CTW’s participation follows its Nasdaq listing in August 2025 and the opening of its first North American office at One World Trade Center in New York City in February 2026. These milestones reflect the Company’s continued efforts to strengthen its presence in the U.S. capital markets and expand engagement with the North American investment community.

The conference will provide an opportunity for CTW to discuss its differentiated business model, portfolio of licensed anime and manga intellectual property, operating execution, user acquisition strategy and long-term growth priorities. CTW believes that consistent, transparent engagement with the investment community is an important element of building market awareness and broadening its institutional shareholder base over time.

Investors attending the conference who are interested in meeting with CTW should contact their BMO Capital Markets representative or CTW’s investor relations team at investor@ctw.inc.

About CTW

CTW is a leading game platform company providing global access to web-based, free-to-play games inspired by popular Japanese anime IP, including So I’m a Spider, So What? Ruler of the Labyrinth, Arifureta: From Commonplace to World’s Strongest – Rebellion Soul, and Queen’s Blade Limit Break. CTW delivers these games through its globally accessible flagship platform, G123.jp, which has accumulated paying users in over 200 countries since its 2018 launch. Founded in Tokyo in 2013, CTW partners with anime and manga IP holders to bring officially licensed titles to players around the world with no downloads or account registration required.

For more information, visit www.ctw.inc or G123.jp.

Safe Harbor Statement

This announcement contains forward-looking statements within the meaning of Section 21E of the U.S. Securities Exchange Act of 1934, as amended. These forward-looking statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “potential,” “continue,” “ongoing,” “targets,” “guidance” and similar statements. CTW may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission (the “SEC”), in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Any statements that are not historical facts, including statements about CTW’s beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: CTW’s growth strategies; its future business development, results of operations and financial condition; its ability to distribute successful and engaging games with high “playability” on its platform; its ability to efficiently attract and retain end-users who come to play and make in-game purchases; its ability to achieve positive return on investment on user acquisition efforts; its ability to establish and maintain relationships with game developers; governmental policies and regulations relating to CTW’s industry; and general economic and business conditions globally and in Japan and assumptions underlying or related to any of the foregoing. Further information regarding these and other risks, uncertainties or factors is included in CTW’s filings with the SEC. All information provided in this press release is as of the date of this press release, and CTW undertakes no obligation to update any forward-looking statement, except as required under applicable law.

Contacts

Media Contact:
CTW Press Team
corpcomm@ctw.inc

Investor Relations Contact:
Patrick Federle | Head of Investor Relations
investor@ctw.inc

• Q3 2026 Financial Results and Business Update Conference Call and Webcast Scheduled for November 5, 2026 at 2:00 p.m. PT/5:00 p.m. ET
• ALLO-329 Autoimmune Disease Program Webinar Featuring Preliminary Safety and Efficacy Data from the Phase 1 RESOLUTION Study Scheduled for November 9, 2026 at 6:00 a.m. PT/9:00 a.m. ET
• Preliminary Data from the Phase 1 RESOLUTION Trial will also be Presented at American College of Rheumatology (ACR) Convergence 2026

SOUTH SAN FRANCISCO, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) — Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today announced two November investor events highlighting third quarter 2026 results and the first clinical update from its ALLO-329 autoimmune disease program.

Q3 2026 Financial Results and General Business Updates
The Company will report third quarter 2026 financial results and provide a business update on November 5, 2026, after the close of the market. The announcement will be followed by a live audio webcast and conference call at 2:00 p.m. PT/5:00 p.m. ET.

• Listen-Only Webcast of the Conference Call
  The listen-only webcast will be made available on the Company’s website at www.allogene.com under the Investors tab in the News and Events section. A replay will be available on the Company’s website for approximately 30 days.
• Conference Call Registration for Questions
  If you would like the option to ask a question on the conference call, please use this link to register. Upon registering for the conference call, you will receive a personal PIN to access the call.

ALLO-329: Autoimmune Disease Program Update from ACR Convergence
The Company will also host a webinar on Monday, November 9, 2026, at 6:00 a.m. PT/9:00 a.m. ET to review preliminary safety and efficacy data from the ongoing Phase 1 RESOLUTION study of ALLO-329 in adults with autoimmune diseases, including lupus, myositis and scleroderma. The webinar will precede the poster presentation of the first clinical results later that day at the American College of Rheumatology’s (ACR) annual meeting, ACR Convergence.

ALLO-329 is an investigational, next-generation off-the-shelf allogeneic CAR T designed to target both CD19 and CD70. It incorporates Allogene’s proprietary Dagger^® technology, which is designed to enhance the expansion and persistence of allogeneic CAR T cells while potentially reducing or eliminating the need for conventional cytotoxic lymphodepletion.

• Listen-Only Version of the Webinar
  The listen-only webinar will be made available on the Company’s website at www.allogene.com under the Investors tab in the News and Events section. A replay will be available on the Company’s website for approximately 30 days.
• Webinar Registration for Questions
  If you would like the option to ask a question on the webinar, please use this link to register. Upon registering for the webinar, you will receive a personal PIN to access the call.

ACR Poster Presentations Details:

• Session: Systemic Sclerosis & Related Disorders – Treatment Poster Session B
• Title: Preliminary Safety and Efficacy Results from a First-in-Human Phase 1 Clinical Study of ALLO-329, a Dual Anti-CD19/Anti-CD70 Allogeneic CAR T-Cell Therapy for Autoimmune Disease
• Presenting Author: Vivek Nagaraja, MD, FACR, Mayo Clinic Arizona
• Date/Time: Monday, November 9, 2026, 10:30 a.m.-12:30 p.m. ET

About Allogene Therapeutics
Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T) products for cancer and autoimmune disease. Led by cell therapy veterans applying proven CAR T experience, Allogene is developing a pipeline of off-the-shelf CAR T cell product candidates with the goal of delivering readily available cell therapy on-demand, more reliably, and at greater scale to more patients. For more information, please visit www.allogene.com, and follow Allogene Therapeutics on X and LinkedIn.

Cautionary Note on Forward-Looking Statements for Allogene
This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things Allogene’s ability to develop and deliver readily available allogeneic CAR T products for the treatment of cancer and autoimmune disease on-demand, more reliably, and at greater scale to more patients. Various factors may cause material differences between Allogene’s expectations and actual results, including risks and uncertainties related to our product candidates being based on novel technologies, which makes it difficult to predict the time and cost of product candidate development, the safety or efficacy of a product candidate, and whether a product candidate will receive regulatory approval, which could prevent or delay commercialization. These and other risks are discussed in greater detail in Allogene’s filings with the SEC, including without limitation under the heading “Risk Factors” in its most recent Annual Report on Form 10-K, Quarterly Report on Form 10-Q, and other filings that Allogene may make from time to time with the SEC. Any forward-looking statements that are made in this press release speak only as of the date of this press release. Allogene assumes no obligation to update the forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

Allogene Media/Investor Contact:
Christine Cassiano
EVP, Chief Corporate Affairs & Brand Strategy Officer
Christine.Cassiano@allogene.com

Company to Host Conference Call and Webcast on November 12, 2026, at 8:30 a.m. ET

FORT WORTH, Texas, Oct. 29, 2026 (GLOBE NEWSWIRE) — Yesway, Inc. (“Yesway” or the “Company”) (Nasdaq: YSWY), one of the fastest-growing convenience store operators in the United States, today announced that it will issue its financial results for the third quarter ended September 30, 2026, before market open on Thursday, November 12, 2026. The Company will host a conference call and webcast to discuss the results that same day at 8:30 a.m. ET.

Webcast Details
A live webcast of the conference call will be available on the investor relations section of the Company’s website or by clicking on the webcast link here.

An online archive of the webcast will be available on the Company’s website for one year following the call.

About Yesway
Established in 2015 and headquartered in Fort Worth, TX, Yesway is an award-winning convenience store operator with approximately 420 stores across eight states in the Midwest and Southwest. Yesway is renowned for its iconic foodservice offerings, diverse grocery selections, and private-label products, including the famous Allsup’s deep-fried burrito. Through strategic acquisitions, the development and opening of more than 90 stores over the past several years, and a steadfast commitment to customer satisfaction and community engagement, Yesway continues to cement its position as one of the leading convenience retailers in the United States.

Investor Contact:
IR@yesway.com

Media Contact:
Erin Vadala
evadala@boltpr.com

Company Reports 500+ U.S. Leads, Expanding Healthcare Network Relationships, Federal Market Access, International Distribution and 300+ Issued and Pending Patents Worldwide

Just 2% Penetration of Estimated U.S. Epidural Procedure Market Represents $33 Million in Potential Annual Disposable Revenue

Medical Segment Revenue Increased 200%+ in Q2 2026 as Company Advances Commercial Expansion and Recurring Revenue Strategy

ROSELAND, N.J., Oct. 29, 2026 (GLOBE NEWSWIRE) — Milestone Scientific Inc. (NYSE American: MLSS), a medical technology company specializing in advanced computerized injection and drug-delivery technologies, today provided a comprehensive commercial update highlighting significant progress in expanding its CompuFlo^® Epidural System across U.S. and international markets.

Milestone believes its proprietary Dynamic Pressure Sensing^® technology addresses a substantial opportunity within an estimated 30 million-plus annual epidural procedures globally, including more than 11 million in the United States.

At just 2% penetration of the estimated U.S. procedure market, approximately 220,000 annual procedures would represent $33 million in potential annual disposable revenue, assuming a $150 selling price per procedure. This illustrative opportunity excludes equipment sales, international markets and potential future medical applications. It is not a revenue projection and assumes clinical eligibility, physician adoption and disposable purchasing.

With an expanded commercial organization, growing physician pipeline, established reimbursement pathways, international distribution and a substantial global patent portfolio, Milestone believes it is positioned to pursue a significantly larger share of this market.

Commercial Expansion and Recent Highlights

• 200%+ Medical Revenue Growth: Medical segment revenue increased 200%+ year-over-year in the second quarter of 2026, demonstrating early commercial momentum.
• 500+ U.S. Commercial Leads: Expanding physician and institutional pipeline generated through targeted sales, digital marketing, medical conferences, physician referrals and clinical outreach.
• Digital Marketing Momentum: Since launching its social media marketing in April 2026, CompuFlo^® social media content has generated more than 217,000 views and approximately 1,600 link clicks through October 27, 2026, expanding awareness among potential customers and supporting physician outreach and lead generation.
• Major Healthcare Network Opportunities: Milestone’s development relationship with Pain and Spine Specialists, led by Dr. Sudhir Rao, spans 22 locations across four states. Additional commercial engagement includes Rothman Orthopaedics, Main Line Health and Memorial Health, representing prospective institutional opportunities at varying stages.
• Growing Physician Adoption: The CompuFlo Advisor Program has generated more than 200 procedure-feedback submissions across approximately 15 sites, supporting clinical experience, physician advocacy and reimbursement development.
• Established Medicare Payment Pathways: Approximately $325 per qualifying CPT^® 0777T procedure has been reported in Novitas and First Coast jurisdictions, with Avania Medical LLC supporting broader reimbursement and market-access initiatives.
• Expanded U.S. Commercial Organization: Five dedicated medical sales professionals, approximately 15 sales consultants, three distribution partners, and additional clinical, reimbursement and physician-advisor resources support market penetration.
• Federal Healthcare Expansion: Strategic distribution partner Red One Medical provides access to VA, Department of Defense, Defense Health Agency and other federal healthcare customers, supporting potential nationwide institutional adoption.
• Growing International Footprint: Clinical education initiatives in Italy reached more than 40 physicians from over 10 hospitals, while relationships with Movi S.p.A. in Italy, Avalon Medical in Qatar and Luxxustone Spa in Chile support broader international expansion.
• Extensive Global Intellectual Property: Approximately 305 issued patents, including approximately 121 CompuFlo-related patents, together with regulatory approvals in 30 countries, support the Company’s technology platform and potential future applications.
• Expanding Clinical Evidence: CompuFlo has been evaluated or utilized at more than 40 universities, academic medical centers and teaching hospitals worldwide, with additional clinical research and academic collaborations underway.

Large Market Opportunity and Recurring Revenue Potential

Milestone believes CompuFlo’s commercial opportunity is supported by the scale of the global epidural market and its recurring-use business model.

Each additional active physician and procedure creates potential demand for the Company’s proprietary disposable products, providing an opportunity to build predictable purchasing patterns as clinical adoption expands.

The Company’s commercial strategy focuses on converting physician interest into active accounts through demonstrations, training, initial procedures, reimbursement support and repeat purchasing.

Milestone believes larger multisite physician practices and healthcare systems provide particularly attractive opportunities, as initial successful adoption may enable expansion across additional physicians and affiliated locations.

Building the Foundation for Broader Market Penetration

Milestone is executing a targeted geographic strategy, initially concentrating commercial resources in Medicare jurisdictions with established payment pathways and expanding into additional regions as physician utilization and reimbursement experience develop.

The Company is increasing its visibility through leading pain and neuromodulation conferences, including ASPN, FSIPP and ISPN, together with physician webinars, hands-on education and engagement with key opinion leaders.

Clinical validation remains a central component of this strategy. A recent 79-patient peer-reviewed University of Texas Medical Branch study associated CompuFlo-guided epidural access during spinal cord stimulator implantation with approximately 91% lower adjusted odds of composite complications compared with conventional loss-of-resistance techniques.

Additional research, including a University of Minnesota evaluation of CathCheck^®, is intended to support broader clinical understanding and utilization across appropriate epidural applications.

Milestone also intends to leverage its broad intellectual-property portfolio to explore additional applications of Dynamic Pressure Sensing^® technology beyond the current epidural market.

Management Commentary

Eric Hines, Chief Executive Officer of Milestone Scientific, commented:

“We believe Milestone is entering an important new phase of commercial growth. We are addressing a large global market with patented technology, growing clinical validation, established reimbursement pathways and a significantly expanded commercial organization.

“The scale of the opportunity is compelling. Just 2% penetration of the estimated U.S. procedure market represents approximately $33 million in potential annual disposable revenue at our illustrative selling-price assumption, before considering international expansion, equipment sales or additional medical applications.

“Our commercial strategy is now focused on converting our growing pipeline of more than 500 U.S. opportunities into active accounts, increasing procedure volumes and expanding successful adoption across larger healthcare networks.

“With growing physician utilization, federal market access, expanding international distribution and a substantial global patent portfolio, we believe the Company has established a stronger foundation for long-term growth.

“Our goal is to scale recurring disposable revenue, replicate successful commercialization across additional markets and continue advancing the clinical and utilization evidence necessary to pursue CPT Category I status, supporting broader adoption of CompuFlo.”

About Milestone Scientific Inc.

Milestone Scientific Inc. is a technology-focused medical research and development company that patents, designs, and develops innovative injection technologies and instruments for medical and dental applications. Milestone Scientific’s computer-controlled systems are designed to make injections precise, efficient and increase the overall patient comfort and safety. Their proprietary DPS Dynamic Pressure Sensing Technology^® instruments is the platform to advance the development of next-generation devices, regulating flow rate and monitoring pressure from the tip of the needle, through platform extensions of subcutaneous drug delivery, including local anesthetic. To learn more, view the MLSS brand video or visit milestonescientific.com.

Safe Harbor Statement

This press release contains forward-looking statements regarding the timing and financial impact of Milestone’s ability to implement its business plan, expected revenues, timing of regulatory approvals and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions, future business decisions and regulatory developments, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone’s control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone’s periodic filings with the Securities and Exchange Commission, including without limitation, Milestone’s Annual Report for the year ended December 31, 2025. The forward-looking statements in this press release are based upon management’s reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

Contact:

HAYDEN IR:

James Carbonara

(646)-755-7412

james@haydenir.com

Brett Maas

(646) 536-7331

brett@haydenir.com

ASHBURN, Va., Oct. 29, 2026 (GLOBE NEWSWIRE) — Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that it plans to provide a corporate update and release its financial results for the third quarter ended September 30, 2026, before the market opens on Thursday, November 5, 2026.

The announcement will include an operational update highlighting key achievements from the quarter, recent accomplishments, and financial highlights from the third quarter of 2026.

About Quoin Pharmaceuticals Ltd.

Quoin Pharmaceuticals Ltd. is a late clinical-stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. We are committed to addressing unmet medical needs for patients, their families, communities and care teams. Quoin’s innovative pipeline is focused on two key platform products, QRX003 and QRX009 that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Pachyonychia Congenita, Gorlin Syndrome and Tuberous Sclerosis Complex, Microcystic Lymphatic Malformations, Venous Malformations, Angiofibromas and others. For more information, visit www.quoinpharma.com or LinkedIn for updates.

For further information, contact:

Quoin Pharmaceuticals Ltd.
Dr. Michael Myers, Ph.D., CEO
mmyers@quoinpharma.com

Investor Relations
PCG Advisory
Jeff Ramson
jramson@pcgadvisory.com
(646) 863-6341

THE WOODLANDS, Texas, Oct. 29, 2026 (GLOBE NEWSWIRE) — Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a leading cardiometabolic biopharmaceutical company, today announced the Company will release its third quarter 2026 financial results on Thursday, November 5, 2026, prior to market open. Management will conduct a conference call and live webcast at 8:30 a.m. ET (7:30 a.m. CT) that day to discuss the financial results and to provide a business update. 

Participants can access the conference call live via webcast on the Events page of the Company’s website at https://investors.lexpharma.com/. Participants who wish to ask a question may register here to receive dial-in numbers and a unique pin to join the call. An archived version of the webcast will be available on the Lexicon website.

About Lexicon Pharmaceuticals
Lexicon Pharmaceuticals is a biopharmaceutical company pursuing novel medicines for patients with serious cardiometabolic diseases. Building on a proven legacy in genetic target discovery, Lexicon is advancing a clinical pipeline in areas of significant and often underserved need, with programs in hypertrophic cardiomyopathy (HCM), type 1 diabetes (T1D), obesity and other related metabolic conditions. Lexicon is committed to developing differentiated therapies that can be integrated broadly into clinical practice, with the goal of expanding treatment options for patients. Its capabilities extend from early-stage target discovery through clinical development and commercialization, strategically paired with high-impact collaborations to maximize the global reach of its medicines.

For additional information, please visit www.lexpharma.com.   

For Media Inquiries:
Dave Belian
Lexicon Pharmaceuticals, Inc.
lexinvest@lexpharma.com

For Investor Inquiries:
Lisa DeFrancesco
Lexicon Pharmaceuticals, Inc.
lexinvest@lexpharma.com

Multi-tenant platform combines fixed-wing VTOL drone operations, crop intelligence, targeted treatment planning, and mission management

Product information and an interactive demonstration are available at evafarmsight.com

LAS VEGAS, NV, Oct. 29, 2026 (GLOBE NEWSWIRE) — Eva Live Inc. (NASDAQ: GOAI) (“Eva” or the “Company”), an artificial intelligence and autonomous technology company, today announced EvaFarmSight, an AI-powered precision agriculture platform designed to connect machine vision, fixed-wing vertical takeoff and landing drone operations, crop monitoring, and field-level decision support.

The public website and interactive product demonstration are available at evafarmsight.com. Current customers can use the same site to sign in to their organization’s secure operating environment.

The initiative marks Eva’s expansion into a major new commercial market, leveraging the Company’s existing investments in artificial intelligence and autonomous systems to address the growing demand for agricultural automation.

According to Grand View Research, the global precision farming market is projected to expand from approximately $16.8 billion in 2026 to $38.8 billion by 2033, representing a compound annual growth rate of 12.7%.

The agricultural drone market, a segment within the broader agricultural technology ecosystem, is separately projected to reach $13.2 billion by 2033, growing at 18.8% annually.

Eva believes these trends present a significant opportunity for companies capable of combining autonomous aerial systems with sophisticated AI analytics.

From Autonomous Defense Technology to the World’s Farmlands

Through its Eva Defense initiative, Eva has been developing autonomous drone concepts, machine vision capabilities, and AI-driven technologies intended for demanding operational environments.

Now, Eva intends to apply relevant elements of those technologies to a different mission: helping farmers protect crops, reduce waste, and operate more efficiently.

EvaFarmSight is designed as a secure, multi-tenant agricultural operations platform that transforms aerial imagery and field data into findings, targeted treatment plans, and flight missions that farm teams can review and manage.

“The same artificial intelligence that can help an autonomous drone identify an object in a complex environment can also help a farmer identify a crop problem across thousands of acres,” said David Boulette, Chief Executive Officer of Eva Live Inc.

“We believe the future of farming will involve autonomous drones continuously gathering intelligence while AI analyzes field conditions and helps farmers make better decisions. Our goal is to make that future practical, affordable, and scalable.”

Giving Every Acre an AI-Powered Eye in the Sky

EvaFarmSight is being designed around a simple concept: farmers should not have to physically inspect every acre to understand what is happening across their land.

The platform’s current and planned capabilities include:

• AI Crop Health Detection: Analyze aerial imagery for signs of potential disease, pest activity, crop stress, and abnormal vegetation patterns, with findings organized by severity and confidence.
• Fixed-Wing VTOL Survey Operations: Support repeatable aerial inspections using long-range aircraft that combine vertical takeoff and landing with efficient fixed-wing field coverage.
• Targeted Treatment Planning: Convert reviewed crop findings into treatment zones and draft prescriptions so farm teams can focus applications on affected areas.
• Precision Water Management: Detect potential irrigation problems, uneven moisture, and drainage patterns that may require field inspection.
• Field Intelligence and Records: Maintain field-level crop information, survey history, findings, and aerial records throughout the growing season.
• Mission and Fleet Management: Plan survey, treatment, and verification missions while monitoring aircraft readiness, battery status, and flight activity.
• Multi-Tenant Agricultural Operations: Separate each customer organization’s farms, fields, aircraft, missions, and user access within a shared platform architecture.

The Company’s longer-term vision includes integrating autonomous aerial monitoring with AI software to create a continuously improving agricultural intelligence system.

A New Recurring Revenue Opportunity for Eva

EvaFarmSight is intended to create opportunities for recurring software revenue, enterprise agricultural licensing, and autonomous monitoring services.

Potential commercial models include subscription-based crop analytics, per-acre monitoring services, enterprise platform licensing, and partnerships with agricultural equipment providers and drone operators.

Unlike traditional agricultural equipment businesses that rely primarily on hardware sales, Eva intends to explore a software-centric model that could generate recurring revenue as farmers use the platform throughout successive growing seasons.

The Company believes this approach could allow EvaFarmSight to scale through agricultural service providers and technology partners without requiring Eva to manufacture or operate every drone used by customers.

Artificial Intelligence Is Moving Beyond the Data Center

EvaFarmSight reflects a broader strategic direction for Eva: commercializing artificial intelligence in industries where software can directly influence real-world operations.

The Company’s initiatives span enterprise AI, autonomous defense systems, machine vision, and now agricultural intelligence.

By applying related technology capabilities across multiple markets, Eva aims to create additional commercialization opportunities from its core research and development activities.

“Agriculture represents a tremendous opportunity because the value of better information can be measured in real economic terms,” Boulette added.

“A farmer who identifies a developing problem earlier may be able to protect an entire section of a field. A farm that optimizes water and fertilizer usage can potentially improve its economics. We want EvaFarmSight to put advanced AI technology to work where those improvements matter.”

Product Platform and Commercial Development

The EvaFarmSight web platform provides a public product overview and interactive demonstration. Within the operating environment, farm teams can review crop health, examine findings by severity and confidence, prepare targeted treatment prescriptions, plan missions, and monitor VTOL aircraft readiness.

The platform uses organization-based roles and server-side tenant controls to separate each customer’s operational data. Eva intends to continue validating EvaFarmSight with agricultural operators, developing industry partnerships, and advancing its autonomous monitoring and analytics capabilities.

Learn more and explore the product at evafarmsight.com.

About Eva Live Inc.

Eva Live Inc. (NASDAQ: GOAI) is an artificial intelligence technology company focused on developing and commercializing advanced AI software, autonomous systems, and intelligent applications across multiple industries. Through its technology initiatives, including Eva Defense, the Company is pursuing opportunities in enterprise artificial intelligence, autonomous technology, machine vision, digital media, and emerging commercial applications.

For more information, visit www.eva.live.

Market Research Sources

Grand View Research, Precision Farming Market Size & Share Report, 2026–2033, June 2026.

Grand View Research, Agriculture Drones Market Size & Share Report, 2026–2033, June 2026.

The market estimates represent third-party industry projections and do not constitute Company revenue forecasts or estimates of EvaFarmSight’s obtainable market share.

Cautionary Note Regarding Forward-Looking Statements.

This press release contains “forward-looking statements” within the meaning of Section 27A of the United States Securities Act of 1933, as amended, and Section 21E of the United States Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, included herein, including but not limited to such things as future business strategy, plans, and goals, and the expansion and growth of our business. The words “estimate”, “plan”, “anticipate”, “expect”, “intend”, “believe” “target”, “budget”, “may”, “can”, “will”, “would”, “could”, “should”, “seeks”, or “scheduled to” and similar words or expressions, or negatives of these terms or other variations of these terms or comparable language or any discussion of strategy or intention identify forward-looking statements. Please see the risk factors included in the Company’s United States Securities and Exchange Commission filings, which could cause actual results and events to differ materially from those contained in the forward-looking statements. You are cautioned against attributing undue certainty to forward-looking statements. Although these forward-looking statements were based on assumptions that the Company believes are reasonable when made, you are cautioned that forward-looking statements are not guarantees of future performance and that actual results, performance, or achievements may differ materially from those made in or suggested by the forward-looking statements in this press release. Any forward-looking statements made in this press release speak only as of the date of those statements. We undertake no obligation to update those statements or publicly announce the results of any revisions to any of those statements to reflect future events or developments.

Media Inquiries:
Javan Khazali
Phone: 310-229-5981
Email: info@eva.live
Website: @eva.live
Instagram: @eva.liveinc
Facebook: @evaliveinc
X: @evaliveinc1
LinkedIn: @eva-live
Youtube: @evaliveinc

WEST DES MOINES, Iowa, Oct. 29, 2026 (GLOBE NEWSWIRE) — West Bancorporation, Inc. (Nasdaq: WTBA; the “Company”), parent company of West Bank, today reported third quarter 2026 net income of $11.6 million, or $0.67 per diluted common share, compared to second quarter 2026 net income of $11.1 million, or $0.64 per diluted common share, and third quarter 2025 net income of $9.3 million, or $0.55 per diluted common share. On October 28, 2026, the Company’s Board of Directors declared a regular quarterly dividend of $0.26 per common share. The dividend is payable on November 25, 2026, to stockholders of record on November 11, 2026.

David Nelson, President and Chief Executive Officer of the Company, commented, “Our net income for the first nine months of 2026 has increased 32 percent compared to the first nine months of 2025. Our annualized return on average equity has improved to 16.18 percent for the first nine months of 2026, compared to 14.27 percent for the first nine months of 2025 and our annualized return on average assets has grown to 1.16 percent in the third quarter of 2026. We are producing stronger profitability through margin expansion and expense discipline, while maintaining a strict underwriting culture and strong asset quality. Our balance sheet management strategies have resulted in a reduction in wholesale funding and steady growth in net interest income.”

Mr. Nelson added, “Our balance sheet remains exceptionally strong, supported by solid capital and liquidity levels. Credit quality remains pristine with no loans on nonaccrual status at September 30, 2026. Additionally, this marks our ninth consecutive quarter-end with no loans greater than 30 days past due.”

Third Quarter 2026 Compared to Second Quarter 2026 Overview

• Quarterly net income was $11.6 million, an increase of $0.5 million, or 5.01 percent, compared to prior quarter.
• Quarterly return on average equity increased to 16.41 percent, compared to 16.21 percent in prior quarter.
• Loan balances increased $45.1 million, or 1.5 percent as of September 30, 2026, compared to June 30, 2026.
• No credit loss expense on loans was recorded in either the third or second quarter of 2026.
• The allowance for credit losses to total loans was 1.02 percent as of September 30, 2026, compared to 1.03 percent as of June 30, 2026. There were no nonaccrual loans at September 30, 2026 or June 30, 2026. Substandard loans decreased to $13.8 million as of September 30, 2026, from $14.4 million as of June 30, 2026. The substandard loan balances consisted of commercial and commercial real estate loans to two borrowers. In both instances, the Company believes the loans are sufficiently collateralized. Watch list loans decreased from $7.1 million as of June 30, 2026 to $6.7 million as of September 30, 2026. The decreases in substandard and and watch list loans was primarily due to principal payments.
• Deposits, excluding brokered deposits, decreased $65.8 million, or 2.0 percent, in the third quarter of 2026. Brokered deposits were reduced by $8.5 million. As of September 30, 2026, estimated uninsured deposits, which exclude deposits in a reciprocal deposit network, brokered deposits and public funds protected by state programs, accounted for approximately 28.5 percent of total deposits.
• Net interest margin, on a fully tax-equivalent basis (a non-GAAP measure), was 2.77 percent for the third quarter of 2026, compared to 2.69 percent for the second quarter of 2026. Net interest income for the third quarter of 2026 was $26.4 million, compared to $25.5 million for the second quarter of 2026. Loan yields increased 8 basis points, to 5.73 percent, in the third quarter of 2026 compared to the second quarter of 2026, while the average balance of loans declined $44.1 million. The cost of interest-bearing deposits increased 3 basis points, to 2.76 percent. The average balance of interest-bearing deposits decreased $36.4 million in the third quarter of 2026 compared to the prior quarter. The comparison of asset yields and cost of interest-bearing deposits is impacted by the 25 basis point increase in the federal funds target rate in September 2026. The average balance of FHLB advances declined $32.1 million in the third quarter of 2026 compared to the prior quarter as matured advances were not renewed.
• The efficiency ratio (a non-GAAP measure) was 47.81 percent for the third quarter of 2026, compared to 48.78 percent for the second quarter of 2026, primarily due to the increase in tax-equivalent net interest income.
• The tangible common equity ratio was 6.98 percent as of September 30, 2026, compared to 6.97 percent as of June 30, 2026.

Third Quarter 2026 Compared to Third Quarter 2025 Overview

• Quarterly net income was $11.6 million, an increase of $2.3 million, or 24.8 percent, compared to prior year.
• Quarterly return on average equity increased to 16.41 percent, compared to 15.25 percent in prior year.
• Loan balances were down slightly by $13.7 million at September 30, 2026, or 0.5 percent, compared to September 30, 2025. Changes in the loan portfolio included decreases of $159.0 million in construction, land and land development loans and $52.9 million in commercial loans and an increase of $156.3 million in commercial real estate loans. The change in loan mix included reclassifications resulting from completed construction projects moving to permanent financing and commercial loan restructurings that added real estate as collateral.
• Deposits, excluding brokered deposits, increased $67.0 million, or 2.2 percent, as of September 30, 2026, compared to September 30, 2025. Brokered deposits were reduced by $102.9 million.
• Net interest margin, on a fully tax-equivalent basis (a non-GAAP measure), was 2.77 percent for the third quarter of 2026, compared to 2.36 percent for the third quarter of 2025. Net interest income for the third quarter of 2026 was $26.4 million, compared to $22.5 million for the third quarter of 2025. Loan yields increased by 7 basis points in the 3rd quarter of 2026, compared to the third quarter of 2025, while the average balance of loans declined $19.6 million. The cost of interest-bearing deposits decreased by 41 basis points in the third quarter of 2026 compared to the third quarter of 2025. The average balance of interest-bearing deposits declined $41.3 million in the third quarter of 2026 compared to the third quarter of 2025. The comparison of asset yields and cost of interest-bearing deposits is impacted by the 75 basis point decrease in the federal funds target rate in the third and fourth quarters of 2025 and subsequent 25 basis point increase in the federal funds target rate in September 2026.
• The efficiency ratio (a non-GAAP measure) was 47.81 percent for the third quarter of 2026, compared to 54.06 percent for the third quarter of 2025. The improvement in the efficiency ratio in the third quarter of 2026 compared to the third quarter of 2025 was primarily due to the increase in tax-equivalent net interest income.

• The tangible common equity ratio was 6.98 percent as of September 30, 2026, compared to 6.40 percent as of September 30, 2025. The increase in the tangible common equity ratio was due to growth in retained earnings.

The Company filed its report on Form 10-Q with the Securities and Exchange Commission today. Please refer to that document for a more in-depth discussion of the Company’s financial results. The Form 10-Q is available on the Investor Relations section of West Bank’s website at www.westbankstrong.com.

The Company will discuss its results in a conference call scheduled for 2:00 p.m. Central Time on Thursday, October 29, 2026. The telephone number for the conference call is 833-461-5787. The meeting ID for the conference call is 761930850. A recording of the call will be available until November 12, 2026, by dialing 833-309-1852. The meeting ID for the replay call is 761930850.

About West Bancorporation, Inc. (Nasdaq: WTBA)

West Bancorporation, Inc. is headquartered in West Des Moines, Iowa. Serving customers since 1893, West Bank, a wholly-owned subsidiary of West Bancorporation, Inc., is a community bank that focuses on lending, deposit services, and trust services for small- to medium-sized businesses and consumers. West Bank has six offices in the Des Moines, Iowa metropolitan area, one office in Coralville, Iowa, and four offices in Minnesota in the cities of Rochester, Owatonna, Mankato and St. Cloud.

Certain statements in this report, other than purely historical information, including estimates, projections, statements relating to the Company’s business plans, objectives and expected operating results, and the assumptions upon which those statements are based, are “forward-looking statements” within the meanings of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Forward-looking statements may appear throughout this report. These forward-looking statements are generally identified by the words “believes,” “expects,” “intends,” “anticipates,” “projects,” “forecasts,” “plans,” “targets,” “future,” “confident,” “potentially,” “probably,” “outlook,” “may,” “should,” “would,” “could,” “will,” “strategy,” “plan,” “opportunity,” “will be,” “will likely result,” “will continue” or similar references, as well as the negative of such words, or references to estimates, predictions or future events. Forward-looking statements are not historical facts but instead represent management’s current expectations and forecasts regarding future events, many of which are inherently uncertain and outside of our control. Such forward-looking statements are based upon certain underlying assumptions, known and unknown, risks and uncertainties. Because of the possibility that the underlying assumptions are incorrect or do not materialize as expected in the future, actual results may differ, possibly materially, from these forward-looking statements. Risks and uncertainties that may affect future results include, but are not limited to: interest rate risk, including the effects of the recent increase in the benchmark federal funds rate by the Federal Reserve; fluctuations in the values of the securities held in our investment portfolio, including as a result of rising interest rates; competitive pressures, including from non-bank competitors such as credit unions, “fintech” companies and digital asset service providers; technological changes implemented by us and other parties, including third-party vendors, which may be more difficult to implement or more expensive than anticipated or which may have unforeseen consequences to us and our customers, including the development and implementation of tools incorporating artificial intelligence; pricing pressures on loans and deposits; our ability to successfully manage liquidity risk; changes in credit and other risks posed by the Company’s loan portfolio, including declines in commercial or residential real estate values or changes in the allowance for credit losses dictated by new market conditions, accounting standards or regulatory requirements; the concentration of large deposits from certain clients, including those who have balances above current FDIC insurance limits; the threat or imposition of domestic or foreign tariffs or other governmental policies impacting the global supply chain and the value of products produced by our commercial borrowers; effects on the U.S. economy resulting from actions taken by the federal government, including executive orders and immigration enforcement; changes in local, national and international economic conditions, including the level and impact of inflation, and future monetary policies of the Federal Reserve in response thereto, and possible recession; the impact of bank failures or adverse developments at other banks and related negative publicity about the banking industry in general on investor and depositor sentiment regarding the stability and liquidity of banks; changes in legal and regulatory requirements, limitations and costs; changes in customers’ acceptance of the Company’s products and services; the occurrence of fraudulent activity, breaches or failures of our or our third-party partners’ information security controls or cyber-security related incidents, including as a result of sophisticated attacks using artificial intelligence and similar tools; unexpected outcomes of existing or new litigation involving the Company; the monetary, trade and other regulatory policies of the U.S. government; the effects of acts of war or terrorism, including the wars in Iran and Ukraine, ongoing conflicts in the Middle East, and other international military conflicts that can increase levels of political and economic unpredictability, contribute to rising energy and commodity prices, affect global supply chains, increase the volatility of financial markets, and other matters beyond our control; widespread disease, pandemics or epidemics, or other adverse external events; risks related to climate change and the negative impact it may have on our customers and their business; changes to U.S. tax laws, regulations and guidance; potential changes in federal policy and at regulatory agencies; talent and labor shortages; emerging issues related to the development and use of artificial intelligence that could give rise to legal or regulatory action, damage our reputation or otherwise materially harm our business or customers; the availability of future equity and debt issuances and other capital raising opportunities on favorable terms; and any other risks described in the “Risk Factors” sections of reports filed by the Company with the Securities and Exchange Commission (the “SEC”). The Company cautions readers not to place undue reliance on any forward-looking statements. Moreover, any of the forward-looking statements that the Company makes in this report or the documents the Company files with or furnishes to the SEC are based only on information then actually known to the Company and upon management’s beliefs and assumptions at the time they are made, which may turn out to be wrong because of inaccurate assumptions they might make, because of the factors described above or because of other factors that the Company cannot foresee. Forward-looking statements speak only as of the date they are made, and the Company does not undertake and specifically disclaims any obligation to revise or update such forward-looking statements to reflect current or future events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

For more information contact:
Jane Funk, Executive Vice President, Treasurer and Chief Financial Officer (515) 222-5766

WEST BANCORPORATION, INC. AND SUBSIDIARY
Financial Information (unaudited)
		As of and for the Quarter Ended																				For the Nine Months Ended
KEY PERFORMANCE RATIOS AND OTHER METRICS		September 30, 2026				June 30, 2026				March 31, 2026				December 31, 2025				September 30, 2025				September 30, 2026				September 30, 2025
Return on average assets(1)			1.16	%			1.10	%			1.06	%			0.72	%			0.92	%			1.11	%			0.84	%
Return on average equity(2)			16.41				16.21				15.91				11.33				15.25				16.18				14.27
Net interest margin(3)(13)			2.77				2.69				2.59				2.47				2.36				2.68				2.30
Yield on interest-earning assets(4)(13)			5.16				5.10				5.04				5.02				5.13				5.10				5.08
Cost of interest-bearing liabilities			2.90				2.88				2.90				3.02				3.26				2.89				3.27
Efficiency ratio(5)(13)			47.81				48.78				49.85				50.21				54.06				48.79				55.60
Nonperforming assets to total assets(6)			0.00				0.00				0.00				0.00				0.00
ACL ratio(7)			1.02				1.03				1.02				1.02				1.01
Loans/total assets			76.96				73.21				74.59				72.47				75.50
Loans/total deposits			91.58				88.20				89.71				86.54				91.00
Tangible common equity ratio(8)			6.98				6.97				6.75				6.42				6.40
COMMON SHARE DATA
Earnings per common share (basic)		$	0.68			$	0.65			$	0.62			$	0.44			$	0.55			$	1.96			$	1.49
Earnings per common share (diluted)			0.67				0.64				0.61				0.43				0.55				1.93				1.48
Dividends per common share			0.26				0.25				0.25				0.25				0.25				0.76				0.75
Book value per common share(9)			15.94				16.49				15.90				15.70				15.06
Closing stock price			28.51				26.53				23.79				22.19				20.32
Market price/book value(10)			178.86	%			160.89	%			149.62	%			141.34	%			134.93	%
Price earnings ratio(11)			10.57				10.18				9.40				12.71				9.31
Annualized dividend yield(12)			3.65	%			3.77	%			4.20	%			4.51	%			4.92	%
REGULATORY CAPITAL RATIOS
Consolidated:
Total risk-based capital ratio			13.43	%			13.46	%			12.99	%			12.77	%			12.54	%
Tier 1 risk-based capital ratio			10.78				10.77				10.34				10.14				9.93
Tier 1 leverage capital ratio			9.18				8.91				8.74				8.44				8.51
Common equity tier 1 ratio			10.21				10.18				9.77				9.56				9.37
West Bank:
Total risk-based capital ratio			13.87	%			13.97	%			13.53	%			13.35	%			13.17	%
Tier 1 risk-based capital ratio			12.95				13.03				12.61				12.44				12.26
Tier 1 leverage capital ratio			11.03				10.79				10.66				10.35				10.50
Common equity tier 1 ratio			12.95				13.03				12.61				12.44				12.26

(1)	Annualized net income divided by average assets.
(2)	Annualized net income divided by average stockholders’ equity.
(3)	Annualized tax-equivalent net interest income divided by average interest-earning assets.
(4)	Annualized tax-equivalent interest income on interest-earning assets divided by average interest-earning assets.
(5)	Noninterest expense (excluding other real estate owned expense and write-down of premises) divided by noninterest income (excluding net securities gains/losses and gains/losses on disposition of premises and equipment) plus tax-equivalent net interest income.
(6)	Total nonperforming assets divided by total assets.
(7)	Allowance for credit losses on loans divided by total loans.
(8)	Common equity less intangible assets (none held) divided by tangible assets.
(9)	Includes accumulated other comprehensive loss.
(10)	Closing stock price divided by book value per common share.
(11)	Closing stock price divided by annualized earnings per common share (basic).
(12)	Annualized dividend divided by period end closing stock price.
(13)	A non-GAAP measure.

 

WEST BANCORPORATION, INC. AND SUBSIDIARY
Financial Information (unaudited)
(in thousands)
		As of
CONDENSED BALANCE SHEETS		September 30, 2026				June 30, 2026				March 31, 2026				December 31, 2025				September 30, 2025
Assets
Cash and due from banks		$	23,155			$	30,986			$	40,018			$	25,171			$	26,875
Interest-earning deposits with banks			88,822				260,633				180,218				324,502				109,265
Securities purchased under agreements to resell			160,444				142,080				141,742				121,413				96,792
Securities available for sale, at fair value			415,648				446,575				456,410				468,447				537,856
Federal Home Loan Bank stock, at cost			12,426				15,168				15,180				15,167				15,190
Loans			2,995,211				2,950,114				2,991,638				3,001,690				3,008,888
Allowance for credit losses			(30,536	)			(30,530	)			(30,523	)			(30,525	)			(30,515	)
Loans, net			2,964,675				2,919,584				2,961,115				2,971,165				2,978,373
Premises and equipment, net			105,510				106,626				107,619				108,380				109,212
Bank-owned life insurance			47,066				46,751				46,500				46,192				45,875
Other assets			73,930				61,261				62,171				61,807				66,042
Total assets		$	3,891,676			$	4,029,664			$	4,010,973			$	4,142,244			$	3,985,480
Liabilities and Stockholders’ Equity
Deposits		$	3,270,646			$	3,344,900			$	3,334,972			$	3,468,470			$	3,306,517
Borrowings			312,852				374,037				375,221				376,406				389,076
Other liabilities			36,488				29,685				30,037				31,383				34,754
Stockholders’ equity			271,690				281,042				270,743				265,985				255,133
Total liabilities and stockholders’ equity		$	3,891,676			$	4,029,664			$	4,010,973			$	4,142,244			$	3,985,480
		For the Quarter Ended
AVERAGE BALANCES		September 30, 2026				June 30, 2026				March 31, 2026				December 31, 2025				September 30, 2025
Assets		$	3,993,933			$	4,029,324			$	4,027,218			$	4,104,279			$	4,004,769
Loans			2,940,392				2,984,527				2,971,497				2,982,754				2,959,962
Deposits			3,335,242				3,347,452				3,348,255				3,418,539				3,333,800
Stockholders’ equity			281,208				273,967				269,453				259,932				242,245

WEST BANCORPORATION, INC. AND SUBSIDIARY
Financial Information (unaudited)
(in thousands)
		As of
LOANS		September 30, 2026				June 30, 2026				March 31, 2026				December 31, 2025				September 30, 2025
Commercial		$	458,416			$	463,248			$	471,423			$	505,059			$	511,316
Real estate:
Construction, land and land development			289,616				333,753				376,059				426,833				448,660
1-4 family residential first mortgages			133,880				130,951				139,118				93,122				87,784
Home equity			26,331				25,999				27,084				26,088				27,083
Commercial			2,068,526				1,977,477				1,958,189				1,929,766				1,912,235
Consumer and other			20,984				21,347				22,257				23,374				24,697
			2,997,753				2,952,775				2,994,130				3,004,242				3,011,775
Net unamortized fees and costs			(2,542	)			(2,661	)			(2,492	)			(2,552	)			(2,887	)
Total loans		$	2,995,211			$	2,950,114			$	2,991,638			$	3,001,690			$	3,008,888
Less: allowance for credit losses			(30,536	)			(30,530	)			(30,523	)			(30,525	)			(30,515	)
Net loans		$	2,964,675			$	2,919,584			$	2,961,115			$	2,971,165			$	2,978,373
CREDIT QUALITY
Pass		$	2,977,301			$	2,931,300			$	2,952,824			$	2,952,015			$	2,973,103
Watch			6,697				7,112				41,306				52,227				38,672
Substandard			13,755				14,363				—				—				—
Doubtful			—				—				—				—				—
Total loans		$	2,997,753			$	2,952,775			$	2,994,130			$	3,004,242			$	3,011,775
DEPOSITS
Noninterest-bearing demand		$	551,615			$	553,660			$	511,013			$	540,358			$	512,869
Interest-bearing demand			436,697				506,574				489,990				577,814				448,731
Savings and money market – non-brokered			1,677,699				1,705,057				1,731,835				1,739,790				1,677,543
Money market – brokered			101,979				100,450				86,304				99,718				121,849
Total nonmaturity deposits			2,767,990				2,865,741				2,819,142				2,957,680				2,760,992
Time – non-brokered			502,656				469,159				485,658				455,944				462,542
Time – brokered			—				10,000				30,172				54,846				82,983
Total time deposits			502,656				479,159				515,830				510,790				545,525
Total deposits		$	3,270,646			$	3,344,900			$	3,334,972			$	3,468,470			$	3,306,517
BORROWINGS
Subordinated notes, net		$	80,352			$	80,287			$	80,221			$	80,156			$	80,090
Federal Home Loan Bank advances			210,000				270,000				270,000				270,000				270,000
Long-term debt			22,500				23,750				25,000				26,250				38,986
Total borrowings		$	312,852			$	374,037			$	375,221			$	376,406			$	389,076
STOCKHOLDERS’ EQUITY
Preferred stock		$	—			$	—			$	—			$	—			$	—
Common stock			3,000				3,000				3,000				3,000				3,000
Additional paid-in capital			38,068				37,312				36,553				37,231				36,473
Retained earnings			314,605				307,408				300,596				294,259				291,069
Accumulated other comprehensive loss			(83,983	)			(66,678	)			(69,406	)			(68,505	)			(75,409	)
Total stockholders’ equity		$	271,690			$	281,042			$	270,743			$	265,985			$	255,133

WEST BANCORPORATION, INC. AND SUBSIDIARY
Financial Information (unaudited)
(in thousands)
		For the Quarter Ended
CONSOLIDATED STATEMENTS OF INCOME		September 30, 2026			June 30, 2026			March 31, 2026			December 31, 2025				September 30, 2025
Interest income:
Loans, including fees		$	42,463		$	42,031		$	40,946		$	41,992			$	42,198
Securities:
Taxable			2,105			2,097			2,143			2,355				2,643
Tax-exempt			634			636			638			677				739
Deposits with banks			2,224			2,130			2,047			2,808				2,087
Securities purchased under agreements to resell			1,769			1,580			1,617			1,370				1,258
Total interest income			49,195			48,474			47,391			49,202				48,925
Interest expense:
Deposits			19,376			19,184			19,261			21,112				22,539
Subordinated notes			1,113			1,110			1,104			1,109				1,107
Federal Home Loan Bank advances			1,965			2,274			2,244			2,316				2,292
Long-term debt			371			385			397			459				486
Total interest expense			22,825			22,953			23,006			24,996				26,424
Net interest income			26,370			25,521			24,385			24,206				22,501
Credit loss expense			—			—			—			—				—
Net interest income after credit loss expense			26,370			25,521			24,385			24,206				22,501
Noninterest income:
Service charges on deposit accounts			482			476			508			493				491
Debit card interchange income			504			514			472			493				477
Trust services			1,190			1,048			1,010			964				894
Increase in cash value of bank-owned life insurance			316			313			308			317				308
Realized securities losses, net			—			—			—			(3,959	)			—
Other income			253			245			256			800				333
Total noninterest income (loss)			2,745			2,596			2,554			(892	)			2,503
Noninterest expense:
Salaries and employee benefits			7,956			7,987			7,632			7,579				7,457
Occupancy and equipment			2,025			2,006			2,006			2,083				2,090
Technology and software			790			822			774			789				794
Data processing			578			545			596			673				663
FDIC insurance			455			444			473			475				637
Professional fees			260			298			278			297				303
Other expenses			1,897			1,665			1,706			1,833				1,606
Total noninterest expense			13,961			13,767			13,465			13,729				13,550
Income before income taxes			15,154			14,350			13,474			9,585				11,454
Income taxes			3,526			3,277			2,902			2,160				2,140
Net income		$	11,628		$	11,073		$	10,572		$	7,425			$	9,314
Basic earnings per common share		$	0.68		$	0.65		$	0.62		$	0.44			$	0.55
Diluted earnings per common share		$	0.67		$	0.64		$	0.61		$	0.43			$	0.55

WEST BANCORPORATION, INC. AND SUBSIDIARY
Financial Information (unaudited)
(in thousands)
		For the Nine Months Ended
CONSOLIDATED STATEMENTS OF INCOME		September 30, 2026			September 30, 2025
Interest income:
Loans, including fees		$	125,440		$	124,852
Securities:
Taxable			6,345			8,116
Tax-exempt			1,908			2,224
Deposits with banks			6,401			6,551
Securities purchased under agreements to resell			4,966			1,280
Total interest income			145,060			143,023
Interest expense:
Deposits			57,821			66,638
Subordinated notes			3,327			3,316
Federal Home Loan Bank advances			6,483			6,786
Long-term debt			1,153			1,508
Total interest expense			68,784			78,248
Net interest income			76,276			64,775
Credit loss expense			—			—
Net interest income after credit loss expense			76,276			64,775
Noninterest income:
Service charges on deposit accounts			1,466			1,448
Debit card interchange income			1,490			1,401
Trust services			3,248			2,472
Increase in cash value of bank-owned life insurance			937			885
Other income			754			950
Total noninterest income			7,895			7,156
Noninterest expense:
Salaries and employee benefits			23,575			21,804
Occupancy and equipment			6,037			6,087
Technology and software			2,386			2,371
Data processing			1,719			1,923
FDIC insurance			1,372			1,894
Professional fees			836			914
Other expenses			5,268			5,105
Total noninterest expense			41,193			40,098
Income before income taxes			42,978			31,833
Income taxes			9,705			6,698
Net income		$	33,273		$	25,135
Basic earnings per common share		$	1.96		$	1.49
Diluted earnings per common share		$	1.93		$	1.48

NON-GAAP FINANCIAL MEASURES

This report contains references to financial measures that are not defined in GAAP. Such non-GAAP financial measures include the Company’s presentation of net interest income and net interest margin on a fully taxable equivalent (FTE) basis and the presentation of the efficiency ratio on an adjusted and FTE basis, excluding certain income and expenses. Management believes these non-GAAP financial measures provide useful information to both management and investors to analyze and evaluate the Company’s financial performance. These measures are considered standard measures of comparison within the banking industry. Additionally, management believes providing measures on a FTE basis enhances the comparability of income arising from taxable and nontaxable sources. Limitations associated with non-GAAP financial measures include the risks that persons might disagree as to the appropriateness of items included in these measures and that different companies might calculate these measures differently. These non-GAAP disclosures should not be considered an alternative to the Company’s GAAP results. The following table reconciles the non-GAAP financial measures of net interest income and net interest margin on a fully taxable equivalent basis and efficiency ratio on an adjusted and FTE basis.

(in thousands)		For the Quarter Ended																				For the Nine Months Ended
		September 30, 2026				June 30, 2026				March 31, 2026				December 31, 2025				September 30, 2025				September 30, 2026				September 30, 2025
Reconciliation of net interest income and net interest margin on a FTE basis to GAAP:
Net interest income (GAAP)		$	26,370			$	25,521			$	24,385			$	24,206			$	22,501			$	76,276			$	64,775
Tax-equivalent adjustment (1)			76				75				72				70				61				223				186
Net interest income on a FTE basis (non-GAAP)			26,446				25,596				24,457				24,276				22,562				76,499				64,961
Average interest-earning assets			3,785,334				3,820,041				3,821,463				3,893,827				3,790,154				3,808,813				3,769,158
Net interest margin on a FTE basis (non-GAAP)			2.77	%			2.69	%			2.59	%			2.47	%			2.36	%			2.68	%			2.30	%
Reconciliation of efficiency ratio on an adjusted and FTE basis to GAAP:
Net interest income on a FTE basis (non-GAAP)		$	26,446			$	25,596			$	24,457			$	24,276			$	22,562			$	76,499			$	64,961
Noninterest income			2,745				2,596				2,554				(892	)			2,503				7,895				7,156
Adjustment for realized securities losses, net			—				—				—				3,959				—				—				—
Adjustment for losses on disposal of premises and equipment, net			7				28				2				—				—				37				8
Adjusted income			29,198				28,220				27,013				27,343				25,065				84,431				72,125
Noninterest expense			13,961				13,767				13,465				13,729				13,550				41,193				40,098
Efficiency ratio on an adjusted and FTE basis (non-GAAP) (2)			47.81	%			48.78	%			49.85	%			50.21	%			54.06	%			48.79	%			55.60	%

(1)

Computed on a tax-equivalent basis using a federal income tax rate of 21 percent, adjusted to reflect the effect of the nondeductible interest expense associated with owning tax-exempt securities and loans. Management believes the presentation of this non-GAAP measure provides supplemental useful information for proper understanding of the financial results, as it enhances the comparability of income arising from taxable and nontaxable sources.

(2)

The efficiency ratio expresses noninterest expense as a percent of fully taxable equivalent net interest income and noninterest income, excluding specific noninterest income and expenses. Management believes the presentation of this non-GAAP measure provides supplemental useful information for proper understanding of the Company’s financial performance. It is a standard measure of comparison within the banking industry. A lower ratio is more desirable.

MINNEAPOLIS, Oct. 29, 2026 (GLOBE NEWSWIRE) — Celcuity Inc. (Nasdaq: CELC), a commercial-stage biotechnology company focused on developing and commercializing targeted therapies for the treatment of multiple solid tumor indications, today announced that it will release its financial results for the third quarter 2026 after the market closes on Thursday, November 5, 2026. Management will host a webcast/teleconference the same day at 4:30 p.m. Eastern Standard Time to discuss the results and provide a corporate update.

Webcast and Conference Call Information

To participate in the teleconference, domestic callers should dial 1-800-717-1738 and international callers should dial 1-646-307-1865. A live webcast presentation can also be accessed using this weblink: https://viavid.webcasts.com/starthere.jsp?ei=1778641&tp_key=e66abcfe8a. A replay of the webcast will be available on the Celcuity website following the live event.

About Celcuity

Celcuity is a commercial-stage biotechnology company focused on developing and commercializing targeted therapies for the treatment of multiple solid tumor indications. The company’s first FDA-approved product is REVTORPYK™ (gedatolisib), a potent pan-PI3K and mTORC1/2 inhibitor that comprehensively blocks the PI3K/AKT/mTOR (“PAM”) pathway. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3Kα, AKT or mTORC1, alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluated gedatolisib in combination with fulvestrant, with or without palbociclib, for the treatment of patients with hormone receptor-positive (“HR+”), human epidermal growth factor receptor 2-negative (“HER2-“) locally advanced or metastatic breast cancer (“ABC”). Data from this trial is the basis for FDA approval of REVTORPYK for use in adult patients with HR+/HER2- ABC without a PIK3CA mutation detected following progression on or after treatment with at least one line of endocrine therapy in the metastatic setting. Results for the PIK3CA mutant cohort of the VIKTORIA-1 study have been released.

Our Phase 3 clinical trial, VIKTORIA-2, is an ongoing trial incorporating two independent studies, Study 1 and Study 2, in two separate cohorts of patients with ABC who are treatment-naive in the advanced setting. Study 1 is evaluating gedatolisib in combination with palbociclib and fulvestrant as first-line treatment for patients with endocrine-resistant HR+/HER2- ABC. Study 2 is evaluating gedatolisib in combination with palbociclib and letrozole as first-line treatment for patients with endocrine-sensitive HR+/HER2- ABC. A Phase 1b/2 clinical trial, CELC-G-201, evaluating gedatolisib in combination with darolutamide in patients with metastatic castration-resistant prostate cancer, is ongoing.

More detailed information about Celcuity’s active clinical trials can be found at ClinicalTrials.gov. Celcuity is headquartered in Minneapolis, Minnesota. Further information about Celcuity and its products, including important safety information and full prescribing information can be found at www.celcuity.com. Follow us on LinkedIn and X.

Contacts: 

Celcuity Inc. 
Brian Sullivan, bsullivan@celcuity.com
Vicky Hahne, vhahne@celcuity.com  
(763) 392-0123  
Jodi Sievers, jsievers@celcuity.com
(415) 494-9924